Objective: To determine the need for home monitoring (HM) for apnea of infancy (AI) beyond 75 weeks post-conceptual age (PCA). HM is often prescribed for AI; however, when AI persists into late infancy, it is often difficult to determine when to discontinue HM. Through a retrospective review of our university-based infant apnea program, 122 infants (total of 1200 infants monitored) were identified who were treated with HM beyond 75 weeks PCA for the period of December, 1990 through December, 1995. Gestational age was 36.9± 4 weeks (SEM), and total monitoring period was 288.6± 10.7 days (SEM). Patients were followed with regular phone contact for the duration of monitoring, and respiratory pattern was determined by impedance pneumocardiogram, event recording monitor (1992 and beyond,) or both, prior to monitor discontinuation. We observed that none of the infants that were asymptomatic at 75 weeks PCA had subsequent episodes of ALTE or SIDS, despite the fact that many had persistent abnormalities on sleep studies. In addition, there was a trend towards poor compliance late in infancy. This data suggests that in asymptomatic infants, it may be appropriate to consider discontinuation of home monitoring by 75 weeks PCA despite persistent abnormalities on sleep studies. At an average monthly charge in Philadelphia of $400.00 for an event recording monitor, continued use beyond 75 weeks PCA does not appear to be cost-effective in this population.